Stafford JA - Search Results

1

Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidines.

Feldman PL, Brackeen MF, Cowan DJ, Marron BE, Schoenen FJ, Stafford JA, Suh EM, Domanico PL, Rose D, Leesnitzer MA, et al. Feldman PL, et al. Among authors: stafford ja. J Med Chem. 1995 Apr 28;38(9):1505-10. doi: 10.1021/jm00009a011. J Med Chem. 1995. PMID: 7739009

2

Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase.

Brackeen MF, Cowan DJ, Stafford JA, Schoenen FJ, Veal JM, Domanico PL, Rose D, Strickland AB, Verghese M, Feldman PL. Brackeen MF, et al. Among authors: stafford ja. J Med Chem. 1995 Nov 24;38(24):4848-54. doi: 10.1021/jm00024a012. J Med Chem. 1995. PMID: 7490734

3

Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesterase.

Stafford JA, Veal JM, Feldman PL, Valvano NL, Baer PG, Brackeen MF, Brawley ES, Connolly KM, Domanico PL, Han B, et al. Stafford JA, et al. J Med Chem. 1995 Dec 22;38(26):4972-5. doi: 10.1021/jm00026a003. J Med Chem. 1995. PMID: 8544172 No abstract available.

4

Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate.

Tian G, Rocque WJ, Wiseman JS, Thompson IZ, Holmes WD, Domanico PL, Stafford JA, Feldman PL, Luther MA. Tian G, et al. Among authors: stafford ja. Biochemistry. 1998 May 12;37(19):6894-904. doi: 10.1021/bi972700v. Biochemistry. 1998. PMID: 9578576

5

Identification and structure-activity studies of novel ultrashort-acting benzodiazepine receptor agonists.

Stafford JA, Pacofsky GJ, Cox RF, Cowan JR, Dorsey GF Jr, Gonzales SS, Jung DK, Koszalka GW, McIntyre MS, Tidwell JH, Wiard RP, Feldman PL. Stafford JA, et al. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3215-8. doi: 10.1016/s0960-894x(02)00512-7. Bioorg Med Chem Lett. 2002. PMID: 12372537

6

Relating the structure, activity, and physical properties of ultrashort-acting benzodiazepine receptor agonists.

Pacofsky GJ, Stafford JA, Cox RF, Cowan JR, Dorsey GF Jr, Gonzales SS, Kaldor I, Koszalka GW, Lovell GG, McIntyre MS, Tidwell JH, Todd D, Whitesell G, Wiard RP, Feldman PL. Pacofsky GJ, et al. Among authors: stafford ja. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3219-22. doi: 10.1016/s0960-894x(02)00513-9. Bioorg Med Chem Lett. 2002. PMID: 12372538

7

Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.

Harris PA, Cheung M, Hunter RN 3rd, Brown ML, Veal JM, Nolte RT, Wang L, Liu W, Crosby RM, Johnson JH, Epperly AH, Kumar R, Luttrell DK, Stafford JA. Harris PA, et al. Among authors: stafford ja. J Med Chem. 2005 Mar 10;48(5):1610-9. doi: 10.1021/jm049538w. J Med Chem. 2005. PMID: 15743202

8

Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.

Sammond DM, Nailor KE, Veal JM, Nolte RT, Wang L, Knick VB, Rudolph SK, Truesdale AT, Nartey EN, Stafford JA, Kumar R, Cheung M. Sammond DM, et al. Among authors: stafford ja. Bioorg Med Chem Lett. 2005 Aug 1;15(15):3519-23. doi: 10.1016/j.bmcl.2005.05.096. Bioorg Med Chem Lett. 2005. PMID: 15990302

9

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.

Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter RN 3rd, Johnson JH, Knick VB, Laudeman CP, Luttrell DK, Mook RA, Nolte RT, Rudolph SK, Szewczyk JR, Truesdale AT, Veal JM, Wang L, Stafford JA. Harris PA, et al. Among authors: stafford ja. J Med Chem. 2008 Aug 14;51(15):4632-40. doi: 10.1021/jm800566m. Epub 2008 Jul 12. J Med Chem. 2008. PMID: 18620382

10

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.

Dev IK, Dornsife RE, Hopper TM, Onori JA, Miller CG, Harrington LE, Dold KM, Mullin RJ, Johnson JH, Crosby RM, Truesdale AT, Epperly AH, Hinkle KW, Cheung M, Stafford JA, Luttrell DK, Kumar R. Dev IK, et al. Among authors: stafford ja. Br J Cancer. 2004 Oct 4;91(7):1391-8. doi: 10.1038/sj.bjc.6602109. Br J Cancer. 2004. PMID: 15328520 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67 results

Search Page

Filters